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BY-NC-ND license (http://creativecomAbstract If portal vein stenosis (PVS) occurs within 1 month after liver transplantation (LT),
especially within 1 week, it can be catastrophic and result in rapid loss of the grafts and mor-
tality. Although surgical treatments have been considered standard treatment for PVS, pa-
tients are usually unable to receive operations or re-transplantations, because of their
critical conditions and a shortage of grafts. Recently, primary percutaneous transhepatic por-
tal vein stents (PTPS) were suggested as alternative and less-invasive treatments of PVS. How-
ever, because lethal complications may follow these primary stent placements for patients in
early stages after LT, primary PTPS placements for patients suffering PVS 1 month after LT has
been suggested. From November 2009 to July 2015, 38 consecutive adult patients underwent
LT at our institution. Among them, six recipients suffered PVS within 1 month after LT. Tech-
nical success was achieved in all six patients. Clinical success was obtained in two of the four
patients suffering PVS within 1 week after LT, and in the other two patients suffering
PVS> 1 week after LT. All surviving patients and their grafts were in good condition, and their
stents remained patent. Our experience showed that primary PTPS placements can be used toeclare no conflicts of interest.
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Stenting for early PVS after LT 129effectively treat patients with PVS encountered within 1 month, and even within 1 week, after
LT with acceptable short-term results. However, possible fatal complications should be kept in
mind. Long-term results of these procedures need further follow-up.
Copyright ª 2016, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. This is an
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Although the rate of portal venous complications, including
primary portal venous anastomotic stenosis or portal vein
thrombosis, in patients who have undergone orthotopic
full-sized liver transplantation (LT) has been reported to be
< 3%, the sequences of these portal venous complications
are usually severe [1e4]. One of the factors determining
the severity of liver-graft dysfunction caused by portal vein
stenosis (PVS) is the interval between the occurrence of
these complications and LT. If PVS occurs during the early
post-transplantation period (i.e., within w2 weeks after
transplantation), it can be catastrophic and result in loss of
the grafts and mortality [5e8]. Surgical treatments, such as
thrombectomy, revasculization, or retransplantation, have
been considered as standard treatments for such compli-
cations [4,6,7,9,10]. Unfortunately, significant morbidity,
mortality, and recurrence rates associated with these sur-
gical procedures have been reported [10,11]. Furthermore,
since there is a shortage of grafts, timely retransplantations
cannot usually be performed for these critical patients.
Due to advances in interventional radiology, percuta-
neous transhepatic balloon venoplasty of portal veins and/
or stent placements in portal veins has been considered as
alternative treatments for posttransplantation PVS
[5,12e14]. However, patients suffering from PVS within
1 month after transplantation usually have ascites and
coagulopathy and develop critical conditions with the
insufficient healing of anastomatoses of portal veins [13].
Lethal complications, such as anastomotic rupture or
massive internal bleeding, may follow these percutaneous
transhepatic procedures in patients that develop PVS within
1 month after transplantation. To avoid complications,
these interventional procedures have previously been
contraindicated in such patients [3,12,13,15]. Thus, pri-
mary percutaneous transhepatic portal vein stent (PTPS)
placements are seldom reported as initial rescue pro-
cedures for patients suffering PVS within 1 week after LT.
Therefore, the aim of this study was to introduce our
preliminary experience and discuss the results, contro-
versies, and concerns regarding the use of primary PTPS
placements in portal veins for treating early PVS within
1 month, and especially within 1 week, after LT.Methods
Patients
From November 2009 to July 2015, 38 consecutive adult
patients (30 males and 8 females ranging in age from35 years to 65 years; mean, 51.8  7.9 years) underwent
LT at our institution. In this retrospective study, we
enrolled 27 patients who received deceased donor LTs
(DDLTs) with full-sized grafts and 11 patients who
received living donor LTs (LDLTs). The protocol for this
study was approved by the Institutional Review Board of
Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
HTK (histidine-tryptophan-a-ketoglutarate) solutions
were used as the preservation solutions in all of our
deceased and living liver grafts. The immunosuppressive
agents used in these patients included induction agents,
basiliximab (20 mg), administered in ahepatic phase and
Day 4 after LT. Standard maintenance immunosuppressive
agents were administered in a triple-drug regimen con-
sisting of tacrolimus, mycophenolate mofetil/or sodium,
and prednisolone (for 3 months).
The diagnosis of PVS was based on findings of Doppler
ultrasound (DUS) initially. A shift in angle-velocity more
than threefold at the focal point narrowing more than the
proximal portion of the PV as shown by DUS raised suspicion
of PVS and was confirmed by computed tomography angi-
ography (CTA) [2,13,16].
The main criterion of PTPS of patients suffering early PVS
was patients had to have abnormal liver function test results
and a CTA showing >50% narrowing of the main PV simul-
taneously [13,16].The abnormal liver function test results,
including prolonged prothrombin time with sudden sharp
increase in aspartate transaminase and alanine transaminase
due to insufficient portal flow, and/or signs of portal hy-
pertension, including ascties, melena, or hematocheaiz
induced by increased resistance of portal system
[2,13,16,17]. Before PTPS procedures, other vascular com-
plications of liver grafts, such as hepatic artery thrombosis,
hepatic vein stenosis, or massive hepatic necrosis, should be
excluded by CTA [17]. And primary non-function, hyperacute
rejection, or severe preservation injury of these allografts
was also excluded clinically before PTPS procedures [17].
Procedure
The procedures have been described previously [13,16].
Briefly, under ultrasonographic and fluoroscopic guidance,
a percutaneous transhepatic puncture of the intrahepatic
PV was performed using a 21-gauge Chiba needle (Cook,
Bloomington, IN, USA). Using the Seldinger technique, the
operator advanced a 0.018-inch wire into the main PV. The
needle was changed to a 4-French coaxial dilator and a 4- or
7-French sheath (Terumo, Tokyo, Japan) over a 0.035-inch
angled hydrophilic guide wire (Terumo). An initial
contrast study to serve as a “road map” was performed
[16]. The guide wire was manipulated to advance beyond
Figure 1. A 61-year-old male patient showed main portal vein stenosis 2 days after liver transplantation. (A) Stricture of
anastomosis of portal vein (arrow) and apparent collateral circulations (arrowhead) of portal vein shown by CTA. Although CTA
showed that there was post-stenotic contrast enhancement of this liver graft, this patient suffered progressive deteriorating liver
function (aspartate transaminase of 2238 IU/L, alanine transaminase of 1402 IU/L, prothrombin time international normalized ratio
of 2.64) due to insufficient portal flow. Therefore, urgent PTPS was performed on this patient to rescue his liver graft. (B)
Transhepatic portal venogram showed a high-grade stenosis (arrow) at the anastomosis of the portal vein. The evident coronary
vein was also observed (arrowhead). (C) A Wallstent (12 mm  60 mm; arrow) was placed to bypass the stenotic portion of the
anastomotic portal vein, and a follow-up portography was performed 1 week later. The portography showed no further anastomotic
stenosis of the portal vein and disappearance of engorged collateral circulation of the portal system. (D) The follow-up abdominal
CTA also showed that the metallic stent (arrow) in the portal vein of the liver graft was patent and in adequate position 35 months
after his liver transplantation. CTA Z computed tomography angiography; PTPS Z percutaneous transhepatic portal vein stents.
130 W.-T. Chang et al.the point of stenosis, and a main PV venography was ob-
tained. A Wallstent (10 mm  60 mm, 12 mm  60 mm,
14 mm  60 mm, or 16 mm  60 mm; Boston Scientific,
Natick, MA, USA) was placed to bypass the stenotic portion
(Figure 1). The percutaneous tract was embolized using
several coils (3 mm  5 cm; Cook) and N-butyl cyanoacry-
late for 3 days to 1 week after these procedures for both
types of patients [13,16]. Pressure gradient was measured
before and after this procedure. Intravenous heparin was
used as anticoagulation therapy after PTPS and adminis-
tered for 7 days to produce a partial thrombin time 1.5e2.0
times; oral antiplatelet agents (clopidogrel 75 mg, aspirin100 mg/d, and/or dipyridamole 75 mg/d) were also pre-
scribed for at least for 6 months [5,13,16,18].
Follow-up
The following parameters were recorded retrospectively:
technical success and clinical success, the patency of the
portal flow, complications, and pressure gradients across a
stenosis before and after primary PTPS [13]. “Technical
success” was defined as stent placement in the intended
location with subsequent improvement of PV flow. “Clinical
success” was defined as subsequent improvement of liver
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Stenting for early PVS after LT 131function and amelioration of clinical manifestations due to
insufficient portal flow [13,16]. Major complications were
defined as those necessitating an increased level of care,
an additional interventional or surgical procedure, adverse
sequelae, or death [13].
The patency of PV was evaluated by follow-up DUS and/
or CTA. The DUS was routinely performed on Day 1, Day 2,
Day 3, and weekly after primary PTPS until the patient was
discharged. Then, DUS was performed every 3 months
thereafter, and CTA was performed if there were any sus-
picious findings of anastomosis of PV as shown by DUS.T
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s.Results
There were five DDLT patients (3 males and 2 females
ranging in age from 51 years to 65 years; mean,
57.1  5.7 years) and one LDLT patient (male, 60 years)
that suffered PVS after LT in this study. All six patients
suffered PVS within 1 month after their LTs, and four of
these six patients suffered PVS within 1 week after their LTs
(Table 1). The initial diagnosis of PVS was impressed by DUS
and confirmed by sequent abdominal CTA and portography
in all six patients.
Reconstruction of the PV during transplantation was
performed by standard end-to-end anastomosis of the
donor and recipient PV in all five DDLT patients (Patients
1e5). Reconstruction of PV of the LDLT patient (Patient 6)
was performed by anastomosis of the main PV of this pa-
tient and right PV of right lobe liver graft. The PVS of Pa-
tients 1e3, 5, and 6 manifested as abnormal liver-function
test results (prolonged prothrombin time and marked in-
crease in liver transmarine). Patient 4 presented compli-
cations of refractory ascites resulting from PVS-related
portal hypertension (Table 1).
Among the six patients with PVS, four patients (Patients
1, 3, 5, and 6) underwent primary PTPS placements within
1 week after their LTs; the other two patients (Patients 2
and 4) received primary PTPS placement 10 days and
25 days after their operations, respectively (Table 1).
Technical success of PTPS was achieved in all six pa-
tients. However, the clinical success rate was 50% in two of
four patients suffering from PVS within 1 week after LT and
100% in two patients suffering from PVS> 1 week after
their LT. The overall clinical success rate was 66.7% in these
patients who had PVS within 1 month after LT (Table 2).
There was no recurrence of PVS encountered in the four
surviving patients, and these patients and their liver grafts
have all remained in good condition thus far. The mean
follow-up periods of the four surviving patients were
55 months, 48 months, 28 months, and 9 months (Table 2).
Two patients (Patients 3 and 5) expired despite technical
success of the PTPS procedures. Both patients had PVS
within 1 week after LT. Patient 3 was a 55-year-old female
patient who underwent primary PTPS 2 days after trans-
plantation. Although her liver function improved, she suf-
fered hepatic artery thrombosis 15 days after
transplantation and expired 20 days later due to septic
shock and multiple organ failure. Patient 5, a 50-year-old
male, underwent primary PTPS 5 days after transplantation
and his liver function also improved. He died 87 days later
due to steroid-resistant cellular rejection.
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132 W.-T. Chang et al.Discussion
Our preliminary experience confirmed the value of primary
PTPS placements in the management of PVS encountered
within 1 month, and even within 1 week, after LT to pre-
vent graft failure and patient death that would result from
subsequent insufficient portal venous flow. Technical suc-
cess was achieved in all patients, and the death of two
“clinical failure” patients was not directly related to the
sequence of PVS or the complications of primary PTPS
placement.
The incidence of PVS in LDLT patients is 2e30%, espe-
cially in pediatric recipients [3,9,16]. However, the rate
of primary PV anastomotic stenosis or PV thrombosis in
patients who have undergone full-sized LT has been re-
ported to be < 3% [1,2]. Early PVS occurring within
1 month after LT is considered to be the sequence of
surgical technical factors, including discrepancy of PV
size, redundant PV length, a tight suture line, tension or
twisting of the PV in the area of the anastomosis, external
compression of the PV due to hematoma, and reactive
edema [2,13]. Compared with the low incidence of PVS
reported by other studies with large numbers of patients,
the rate of PVS (19.3%) of our DDLT patients was signifi-
cantly higher. This unsatisfactory result may be due to the
learning curve encountered when beginning a new LT
program. Since refining our surgical technique, there has
been no PVS encountered in our DDLT patients since
November 2013.
Surgical intervention or retransplantation has been
suggested as the standard treatments of PVS after LT [2,9].
Unfortunately, the roles of surgical treatments for early
PVS are limited due to either their technical difficulty as a
result of postsurgical fibrosis and limitations in the length of
the involved venous structures making it impossible to
perform some procedures on some critical patients or
because of a shortage of liver grafts [2,13]. Additionally,
many patients are not fit to receive operations due to their
critical conditions, putting them at risk for surgical treat-
ments of early PVS, which has been associated with sig-
nificant morbidity, mortality, and recurrence rates [3,4,10].
Furthermore, we anticipated that noninvasive therapy
(antithrombotic therapy) would be ineffective in its
correction of the mechanical disorders of PVS. Because of
advancements in interventional radiology, we decided to
use primary PTPS placements. There are few reports on this
means of treating very early PVS.
Although the procedures used in this study achieved
acceptable results with regard to saving both patients and
grafts, some controversies regarding their use still exist.
One of the major concerns is the efficacy and safety of
these procedures when performed on patients suffering
from very early PVS after transplantation. There might not
be sufficient healing of a vascular anastomosis within
1 month following LT, as the recipients have also undergone
immunosuppressive treatment [13]. The other concerns are
that the grafts are not usually fixed and that the recipients
may also have coagulopathy or ascites within 2 weeks after
LT [5,19]. Furthermore, PVS itself might induce coagulop-
athy or the development of ascites in recipients. Thus, the
possibility of anastomotic rupture, liver parenchyma injury,
Stenting for early PVS after LT 133and massive internal bleeding induced by this procedure
cannot be excluded [6,13,19]. Therefore, until recently,
these percutaneous transhepatic procedures, including
primary stenting and balloon angioplasty for PVS, were
usually suggested for patients with late PVS (> 30 days or
> 90 days after transplantation) rather than in patients
with early PVS [3,8,9,12,13,15,16,20]. Furthermore, the
high incidence of restenosis of PVS after percutaneous
balloon dilation of late PVS has been reported previously
[8,18].
Therefore, we used primary PTPS placement instead of
balloon dilation of PV only to treat PVS encountered within
1 month after LT in our patients. Carnevale et al. [21] were
the first to report success with direct transhepatic balloon
angioplasty and stent placement in a patient with early PVS
on postoperative Day 8. Later, Ko et al. [13] reported their
experience performing primary PTPS placements for early
posttransplantation PVS (within 1 month). Nine LDLT pa-
tients (0.8% of their series) were enrolled in their study, and
four of their patients had diagnoses of PVS within 1 week
after LT. Technical success was achieved in these four pa-
tients; however, major complications, including hemoper-
itoneum, were encountered in two of the patients (50%)
and technical failure occurred in two patients (50%).
Additionally, three patients (75%) died due to multiorgan
failure and intracranial hemorrhage within 1 month after
their transhepatic procedures [13].
Thus, even in an experienced LT programs with large
surgical volumes there remains an association between PVS
encountered within 1 week after LT and morbidity and
mortality in high-risk patients [13]. Similarly, in this study,
two patients died due to hepatic artery thrombosis and
steroid-resistant cellular rejection, despite the technical
success of primary PTPS placements achieved in both of
them.
Possibly due to the early detection of PVS in our pa-
tients, we found only one patient to have moderate
amounts of ascites and none to have melena or hematem-
esis due to ruptured gastric or esophageal varices (Table 1).
We performed drainage of her ascites, while simultaneously
performing primary PTPS placement. There was no
procedure-related hemoperitoneum or rupture of anasto-
mosis of PVs encountered in our patients.
Nevertheless, care must be taken when placing the stent
in a position where the metallic object will not interfere
with further retransplantation [22], and some authors have
suggested that intravascular metallic stents should not be
deployed due to the possible need for retransplantation in
patients suffering from late PVS. In these cases, repeat
balloon dilation of PVS was suggested [12]. However, these
suggestions remain controversial, as other authors have
found that the stents can be excised at the time of
retransplantation or left in situ, with new anastomosis
performed at the level of the superior mesenteric vein [3].
Additionally, the long-term patency rate of these stents
should be considered [14,18]. Some suggest routine three-
combined anticoagulation agents be administrated to
these patients to prevent thrombosis of these metallic
stents [5,18]. Accordingly, anticoagulation therapies were
prescribed in our four patients surviving after primary PTPS
procedures. To date, there has been no occlusion of their
stents.In conclusion, although there were a relatively small
number of patients enrolled in this study, our experience
suggested that primary PTPS is a feasible and effective
alternative rescue procedure for patients suffering from
early symptomatic PVS within 1 month, and even within
1 week, after LT. However, the criteria for using primary
PTPS in patients needs further clarification, and the
possible lethal complications of these procedures should be
kept in mind. Randomized studies would be ideal to
compare the results between the use of primary PTPS and
surgical intervention in treating early PVS after LT, though
this is difficult for practical reasons. Finally, although the
short-term results of these procedures were acceptable,
the long-term results need further observation.References
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